Cuprymina

RSS

copper (64Cu) chloride

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Cuprymina. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cuprymina.

This EPAR was last updated on 24/03/2020

Authorisation details

Product details
Name
Cuprymina
Agency product number
EMEA/H/C/002136
Active substance
copper (64Cu) chloride
International non-proprietary name (INN) or common name
copper (64Cu) chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
-
Publication details
Marketing-authorisation holder
A.C.O.M. - Advanced Center Oncology
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
23/08/2012
Contact address

Macerata - S.R.L.
Località Cavallino 39 A/B
62010 Montecosaro (MC)
Italy

Product information

28/02/2020 Cuprymina - EMEA/H/C/002136 - T/0022

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

various

Therapeutic indication

Cuprymina is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.

Assessment history

How useful was this page?

Add your rating